New Information on Peripheral Artery Disease (PAD) and High Blood Pressure Medication from USA Vascular Centers

August 08, 2023 06:16 PM CEST | By EIN Presswire
 New Information on Peripheral Artery Disease (PAD) and High Blood Pressure Medication from USA Vascular Centers
Image source: EIN Presswire

Minimally invasive treatment proves more successful than medication in alleviating PAD symptoms.

NORTHBROOK, IL, UNITED STATES, August 8, 2023/EINPresswire.com/ -- USA Vascular Centers, a national network of vascular care providers specializing in minimally invasive peripheral artery disease treatments, monitors new research and information on PAD treatments to offer the most innovative treatment options.

Peripheral artery disease (PAD) is a disease of the arteries in the legs that causes poor blood flow. It occurs when narrowed arteries restrict blood supply to the limbs. It is a significant risk factor for heart attack, stroke, and amputation.

PAD affects 8 to 12 million people in the United States, especially those over 50. High blood pressure along with smoking, atherosclerosis, diabetes, high cholesterol and age are risk factors for PAD.

High blood pressure, or hypertension, poses a significant risk factor for PAD because it facilitates plaque buildup in the arteries that can lead to partial or complete blockage. When arteries are narrow, blood pressure rises, causing stress on the heart and potential artery damage. This combination of high blood pressure and plaque buildup can be life-threatening.

A 2023 report recently released from the American Heart Association identified that nearly half of Americans ages 20 and older – more than 122 million people- have high blood pressure.[1] Among Americans aware they have high blood pressure, 88 percent manage their condition with medication.

USA Vascular Centers is alerting its patients and the public about the findings of a recent study that used a blood pressure medication to treat peripheral artery disease (PAD). The recent study found that the blood pressure medication did not improve walking performance or alleviate PAD symptoms in patients with lower extremity PAD.

“Treatment is important because having PAD is a sign that your blood vessels are unhealthy,” said CEO and Founder of USA Vascular Centers, Dr. Yan Katsnelson, a Harvard-trained cardiothoracic and vascular surgeon. “We want people to know that non-surgical effective treatment options are available, especially when medication is ineffective.”

Treatments for PAD offered by vascular specialists at USA Vascular Centers promote better blood flow, improve mobility, and reduce the risk of heart attack, stroke, and limb amputation. Depending on the diagnosis and progression of PAD disease, minimally invasive treatments include angioplasty, stent placement, and atherectomy. These non-surgical outpatient treatments do not require any hospital stay. They can help reduce plaque blockages while improving blood flow and circulation.

For more information, call 888-773-2193 or visit www.usavascularcenters.com to learn more.

About USA Vascular Centers

USA Vascular Centers are dedicated to the minimally invasive, non-surgical treatment of various conditions, including Peripheral Artery Disease (PAD). At USA Vascular Centers, highly trained vascular specialists offer minimally invasive treatments for vascular diseases that used to require surgery and a hospital stay. For information, visit www.usavascularcenters.com.

[1] American Heart Association Heart and Stroke Update 2023: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://professional.heart.org/-/media/PHD-Files-2/Science-News/2/2023-Heart-and-Stroke-Stat-Update/2023-Statistics-At-A-Glance-final_1_17_23.pdf

News Center
USA Vascular Centers
+1 847-737-4983
email us here


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles